<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Earl&#039;s View &#187; Elderly Patients</title>
	<atom:link href="/category/elderly-patients-2/feed/" rel="self" type="application/rss+xml" />
	<link>https://earlsview.com</link>
	<description>News and Views</description>
	<lastBuildDate>Tue, 10 Dec 2013 23:26:54 +0000</lastBuildDate>
	<language>en</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='earlsview.com' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
 &#187; Elderly Patients<image>
		<url>http://0.gravatar.com/blavatar/4080c5ddab1377b030361fa4f366fc3d?#038;d=http%3A%2F%2Fs2.wp.com%2Fi%2Fbuttonw-com.png</url>
		<title>Earl&#039;s View</title>
		<link>https://earlsview.com</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="/osd.xml" title="Earl&#039;s View" />
	<atom:link rel='hub' href='/?pushpress=hub'/>
	<item>
		<title>OUT OF CONTROL &#8211; Johnson &amp; Johnson Fined $2.2 Billion for Reckless Drug Distribution</title>
		<link>https://earlsview.com/2013/11/20/out-of-control-johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/</link>
		<comments>https://earlsview.com/2013/11/20/out-of-control-johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/#comments</comments>
		<pubDate>Tue, 19 Nov 2013 19:56:40 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[elderly]]></category>
		<category><![CDATA[Elderly Patients]]></category>
		<category><![CDATA[Hip Replacement]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson & Johnson lawsuit]]></category>
		<category><![CDATA[$2.2 billion]]></category>
		<category><![CDATA[Antipsychotic]]></category>
		<category><![CDATA[Eric Holder]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Nesiritide]]></category>
		<category><![CDATA[Omnicare]]></category>
		<category><![CDATA[Risperidone]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=9835</guid>
		<description><![CDATA[Johnson &#38; Johnson Fined $2.2 Billion for Reckless Drug Distribution &#8211; Florida Mass Tort Attorneys, Lawyers &#124; Searcy Mass Torts. &#8230;<p><a href="/2013/11/20/out-of-control-johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=9835&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.searcymasstort.com/blog/2013/11/19/johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/#.UovBWu5Rgf4.wordpress">Johnson &amp; Johnson Fined $2.2 Billion for Reckless Drug Distribution &#8211; Florida Mass Tort Attorneys, Lawyers | Searcy Mass Torts</a>.</p>
<h1>Johnson &amp; Johnson Fined $2.2 Billion for Reckless Drug Distribution</h1>
<p>Posted on November 19, 2013 by Cal Warriner</p>
<p>One has to wonder how this will play with stockholders. Johnson &amp; Johnson, the healthcare giant, has agreed to pay more than $2.2 billion to settle criminal charges over the marketing of its <a class="zem_slink" title="Antipsychotic" href="http://en.wikipedia.org/wiki/Antipsychotic" target="_blank" rel="wikipedia">antipsychotic drug</a>, <a class="zem_slink" title="Risperidone" href="http://en.wikipedia.org/wiki/Risperidone" target="_blank" rel="wikipedia">Risperdal</a>. The company’s <a class="zem_slink" title="Janssen Pharmaceutica" href="http://www.janssenpharmaceuticalsinc.com/" target="_blank" rel="homepage">Janssen Pharmaceuticals</a> division is accused of marketing the drug to treat elderly patients with dementia, children and the disabled.</p>
<p>This case, brought by the <a class="zem_slink" title="United States Department of Justice" href="http://maps.google.com/maps?ll=38.89325,-77.0249722222&amp;spn=0.01,0.01&amp;q=38.89325,-77.0249722222 (United%20States%20Department%20of%20Justice)&amp;t=h" target="_blank" rel="geolocation">Department of Justice</a>, is a big win for American patients.</p>
<p>Risperdal was approved 20 years ago by the <a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0352777778,-76.9830555556&amp;spn=0.01,0.01&amp;q=39.0352777778,-76.9830555556 (Food%20and%20Drug%20Administration)&amp;t=h" target="_blank" rel="geolocation">U.S. Food and Drug Administration (FDA)</a> for managing psychotic disorders, not to keep the elderly subdued or children quiet.</p>
<p>In announcing the settlement this week, <a class="zem_slink" title="United States Attorney General" href="http://en.wikipedia.org/wiki/United_States_Attorney_General" target="_blank" rel="wikipedia">U.S. Attorney General</a> <a class="zem_slink" title="Eric Holder" href="http://en.wikipedia.org/wiki/Eric_Holder" target="_blank" rel="wikipedia">Eric Holder</a> called it among the largest healthcare fraud settlements in U.S. history.</p>
<p>J&amp;J marketed Risperdal for unapproved uses from 1999 through 2005. And it had help. <a class="zem_slink" title="Omnicare" href="http://www.omnicare.com/" target="_blank" rel="homepage">Omnicare</a>, which dispenses drugs to nursing homes, billed the government for the unapproved drugs, and received kickbacks from Risperdal sales reps to prescribe the drug as well as another antipsychotic, Invega (for the treatment of schizophrenia) and <a class="zem_slink" title="Nesiritide" href="http://en.wikipedia.org/wiki/Nesiritide" target="_blank" rel="wikipedia">Natrecor</a>, a heart drug, according to a report in Bloomberg.</p>
<p>- See more at: <a href="http://www.searcymasstort.com/blog/2013/11/19/johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/#sthash.exfHp6zJ.dpuf" target="_blank">http://www.searcymasstort.com/blog/2013/11/19/johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/#sthash.exfHp6zJ.dpuf</a></p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="http://www.undergroundhealth.com/johnson-johnson-illegally-paid-doctors-and-pharmacies-kickbacks-to-promote-prescription-drugs-for-unapproved-uses/" target="_blank">Johnson &amp; Johnson illegally paid doctors and pharmacies kickbacks to promote prescription drugs for &#8220;unapproved uses&#8221;</a> (undergroundhealth.com)</li>
<li class="zemanta-article-ul-li"><a href="http://r.zemanta.com/?u=http%3A//www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html&amp;a=217658505&amp;rid=0000006f-f097-000F-0000-00000000266b&amp;e=8b3a1058828d56ad379fec2619a6de34" target="_blank">Johnson &amp; Johnson to Settle Risperdal Improper Marketing Case</a> (nytimes.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.newsday.com/business/johnson-johnson-to-pay-2b-to-settle-psychiatric-drug-charges-1.6378466" target="_blank">Johnson &amp; Johnson to pay $2B to settle psychiatric drug charges</a> (newsday.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.abc.net.au/news/2013-11-05/jj-fined-22bn-for-faulty-drug-claims-kickbacks/5070346" target="_blank">Johnson &amp; Johnson fined $2.2 billion for faulty drug claims</a> (abc.net.au)</li>
<li class="zemanta-article-ul-li"><a href="http://consumerist.com/2013/11/04/johnson-johnson-to-pay-2-2-billion-to-settle-deceptive-marketing-claims/" target="_blank">Johnson &amp; Johnson To Pay $2.2 Billion To Settle Deceptive Marketing Claims</a> (consumerist.com)</li>
<li class="zemanta-article-ul-li"><a href="http://onntimes.com/2013/11/05/johnson-johnson-fined-2-2bn-to-settle-drug-cases/" target="_blank">Johnson &amp; Johnson fined $2.2bn to settle drug cases</a> (onntimes.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.thehindu.com/business/Industry/johnson-johnson-pleads-guilty-to-fraud/article5318076.ece" target="_blank">Johnson &amp; Johnson pleads guilty to fraud</a> (thehindu.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.newser.com/story/177010/johnson-johnson-will-pay-22b-over-kickbacks.html" target="_blank">Johnson &amp; Johnson Will Pay $2.2B Over Kickbacks</a> (newser.com)</li>
<li class="zemanta-article-ul-li"><a href="http://r.zemanta.com/?u=http%3A//www.cbsnews.com/8301-204_162-57610705/johnson-johnson-to-pay-%242.2b-in-u.s-health-care-fraud-settlement/&amp;a=217626792&amp;rid=0000006f-f097-000F-0000-00000000266b&amp;e=f3c11c1d6d429dc5c6337133c067ff4a" target="_blank">Johnson &amp; Johnson to pay $2.2B in health care fraud settlement</a> (cbsnews.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.abqjournal.com/294207/biz/doj-johnson-amp-johnson-agrees-to-pay-22b.html" target="_blank">DOJ: Johnson &amp; Johnson agrees to pay $2.2B</a> (abqjournal.com)</li>
</ul><br />Filed under: <a href='/category/elderly/'>elderly</a>, <a href='/category/elderly-patients-2/'>Elderly Patients</a>, <a href='/category/hip-replacement/'>Hip Replacement</a>, <a href='/category/johnson-johnson/'>Johnson &amp; Johnson</a>, <a href='/category/johnson-johnson-lawsuit/'>Johnson &amp; Johnson lawsuit</a> Tagged: <a href='/tag/2-2-billion/'>$2.2 billion</a>, <a href='/tag/antipsychotic/'>Antipsychotic</a>, <a href='/tag/eric-holder/'>Eric Holder</a>, <a href='/tag/food-and-drug-administration/'>Food and Drug Administration</a>, <a href='/tag/johnson/'>Johnson</a>, <a href='/tag/johnson-johnson/'>Johnson &amp; Johnson</a>, <a href='/tag/nesiritide/'>Nesiritide</a>, <a href='/tag/omnicare/'>Omnicare</a>, <a href='/tag/risperidone/'>Risperidone</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/9835/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/9835/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=9835&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2013/11/20/out-of-control-johnson-johnson-fined-2-2-billion-for-reckless-drug-distribution/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Primary Total Resurfacing Hip Replacement – Extracts from Australian Orthopaedic Association National Joint Replacement Registry – Annual Report 2010</title>
		<link>https://earlsview.com/2011/08/06/primary-total-resurfacing-hip-replacement-%e2%80%93-extracts-from-australian-orthopaedic-association-national-joint-replacement-registry-%e2%80%93-annual-report-2010/</link>
		<comments>https://earlsview.com/2011/08/06/primary-total-resurfacing-hip-replacement-%e2%80%93-extracts-from-australian-orthopaedic-association-national-joint-replacement-registry-%e2%80%93-annual-report-2010/#comments</comments>
		<pubDate>Sat, 06 Aug 2011 12:52:17 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[Australian Joint Registry]]></category>
		<category><![CDATA[Birmingham Hip Replacement video]]></category>
		<category><![CDATA[Birmingham Hip Resurfacing]]></category>
		<category><![CDATA[DePuy ASR Hip]]></category>
		<category><![CDATA[DePuy Hip Litigation]]></category>
		<category><![CDATA[DePuy Hip Recall]]></category>
		<category><![CDATA[DePuy Hip Replacement]]></category>
		<category><![CDATA[DePuy Lawsuit]]></category>
		<category><![CDATA[Elderly Patients]]></category>
		<category><![CDATA[hip implants]]></category>
		<category><![CDATA[Hip Pain]]></category>
		<category><![CDATA[Hip Replacement]]></category>
		<category><![CDATA[Hip Resurfacing]]></category>
		<category><![CDATA[Hip Revisions]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson & Johnson lawsuit]]></category>
		<category><![CDATA[Joint replacement]]></category>
		<category><![CDATA[Metal on metal hip]]></category>
		<category><![CDATA[Total Hip Replacement]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[Avascular necrosis]]></category>
		<category><![CDATA[bearing surface]]></category>
		<category><![CDATA[Femur head]]></category>
		<category><![CDATA[hip resurfacing]]></category>
		<category><![CDATA[osteoarthritis]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Prosthesis]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=4314</guid>
		<description><![CDATA[Primary Total Resurfacing Hip Replacement &#160; Demographics There have been 13,307 total resurfacing procedures reported to the Registry, an additional &#8230;<p><a href="/2011/08/06/primary-total-resurfacing-hip-replacement-%e2%80%93-extracts-from-australian-orthopaedic-association-national-joint-replacement-registry-%e2%80%93-annual-report-2010/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4314&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<h3>Primary Total Resurfacing <a class="zem_slink" title="Hip Replacement Surgery" href="http://arthritis.webmd.com/hip-replacement-surgery" rel="webmd">Hip Replacement</a></h3>
<p>&nbsp;</p>
<h3>Demographics</h3>
<p>There have been 13,307 total resurfacing procedures reported to the Registry, an additional 1,214 procedures compared to the last report. <em><strong>The use of resurfacing hip replacement in <a class="zem_slink" title="Australia" href="http://maps.google.com/maps?ll=-35.3,149.133333333&amp;spn=1.0,1.0&amp;q=-35.3,149.133333333%20%28Australia%29&amp;t=h" rel="geolocation">Australia</a> continues to decline.</strong></em> The number of procedures reported in 2009 was 17.6% less than 2008 and 34.6% less compared to the peak in 2005.</p>
<p>Osteoarthritis is the principal <a class="zem_slink" title="Diagnosis" href="http://en.wikipedia.org/wiki/Diagnosis" rel="wikipedia">diagnosis</a> for total resurfacing hip replacement (94.6%), followed by developmental <a class="zem_slink" title="Dysplasia" href="http://en.wikipedia.org/wiki/Dysplasia" rel="wikipedia">dysplasia</a> (2.7%), <a class="zem_slink" title="Avascular Necrosis Osteonecrosis Symptoms Treatments" href="http://arthritis.webmd.com/avascular-necrosis-osteonecrosis-symptoms-treatments" rel="webmd">avascular necrosis</a> (1.8%), rheumatoid arthritis (0.4%) and other <a class="zem_slink" title="Rheumatoid arthritis" href="http://en.wikipedia.org/wiki/Rheumatoid_arthritis" rel="wikipedia">inflammatory arthritis</a> (0.4%).</p>
<p>Most patients are male and the proportion of <a class="zem_slink" title="Male" href="http://en.wikipedia.org/wiki/Male" rel="wikipedia">males</a> has increased from 71.2% in 2003 to 83.7% in 2009 (Figure HT31).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-31.png"><img class="aligncenter size-full wp-image-4315" title="Figure HT 31" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-31.png?w=529" alt=""   /></a></p>
<p>There has been a slight increase in patients younger than 55 years since 2005 (49.1% in 2005 to 56.6% in 2009) (Figure HT32).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-32.png"><img class="aligncenter size-full wp-image-4316" title="Figure HT 32" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-32.png?w=529" alt=""   /></a></p>
<p>The majority of total resurfacings use hybrid fixation (94.0% in 2009), however there has been an increase in the proportion of cementless fixation, increasing from 2.3% in 2003 to 5.8% in 2009. The <a class="zem_slink" title="Bearing surface" href="http://en.wikipedia.org/wiki/Bearing_surface" rel="wikipedia">bearing surface</a> for resurfacing hip replacement is metal/metal in almost all cases.</p>
<p>The <a class="zem_slink" title="Hip resurfacing" href="http://en.wikipedia.org/wiki/Hip_resurfacing" rel="wikipedia">BHR</a> remains the most used resurfacing hip prosthesis (68.1%) but is declining in use. The Mitch TRH, ASR and Durom have also shown a decline in use in 2009 (Table HT57).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-57.png"><img class="aligncenter size-full wp-image-4317" title="Table HT 57" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-57.png?w=529&#038;h=331" alt="" width="529" height="331" /></a></p>
<h3>Outcome</h3>
<p>The cumulative percent revision at nine years for primary total resurfacing hip replacement undertaken for <a class="zem_slink" title="Osteoarthritis" href="http://en.wikipedia.org/wiki/Osteoarthritis" rel="wikipedia">osteoarthritis</a> is 7.2% (Table HT58 and Figure HT33).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-58.png"><img class="aligncenter size-full wp-image-4318" title="Table HT 58" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-58.png?w=529&#038;h=94" alt="" width="529" height="94" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-33.png"><img class="aligncenter size-full wp-image-4319" title="Figure HT 33" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-33.png?w=529&#038;h=329" alt="" width="529" height="329" /></a></p>
<h3>Reasons for Revision</h3>
<p>The main reasons for revision of primary resurfacing hip replacements are fracture (35.6%), loosening/lysis (33.4%), infection (8.2%), metal sensitivity (7.1%) and pain (5.3%) (Table HT59).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-59.png"><img class="aligncenter size-full wp-image-4320" title="Table HT 59" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-59.png?w=529" alt=""   /></a></p>
<p>The five most common reasons for revision are shown in Figure HT34.</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-34.png"><img class="aligncenter size-full wp-image-4321" title="Figure HT 34" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-34.png?w=529" alt=""   /></a></p>
<p>The <a class="zem_slink" title="Incidence (epidemiology)" href="http://en.wikipedia.org/wiki/Incidence_%28epidemiology%29" rel="wikipedia">incidence</a> of revision for fracture increases rapidly in the first year, however after this time the incidence increases at a slower rate. Loosening/lysis shows a linear increase and at six years exceeds fracture to become the most common reason for revision. The remaining reasons for revision have a low incidence.</p>
<h3>Type of Revision</h3>
<p>The main types of revision of resurfacing hip replacement are isolated femoral (52.4%), total hip replacement (36.7%) and acetabular only (7.5%) (Table HT60).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-60.png"><img class="aligncenter size-full wp-image-4322" title="Table HT 60" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-60.png?w=529" alt=""   /></a></p>
<h3>Primary Diagnosis</h3>
<p>The outcomes of the three most common primary diagnoses (osteoarthritis, developmental dysplasia and avascular necrosis) are listed in Tables HT61 and HT62.</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-61.png"><img class="aligncenter size-full wp-image-4323" title="Table HT 61" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-61.png?w=529&#038;h=160" alt="" width="529" height="160" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-62.png"><img class="aligncenter size-full wp-image-4324" title="Table HT 62" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-62.png?w=529&#038;h=127" alt="" width="529" height="127" /></a>Primary resurfacing hip replacement for osteoarthritis has a significantly <a class="zem_slink" title="Lower Risk" href="http://en.wikipedia.org/wiki/Lower_Risk" rel="wikipedia">lower risk</a> of revisioncompared to developmental dysplasia (Figure HT35).</p>
<h3><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-35.png"><img class="aligncenter size-full wp-image-4326" title="Figure HT 35" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-35.png?w=529&#038;h=359" alt="" width="529" height="359" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-351.png"><br />
</a>Age and Gender</h3>
<p>There is a higher risk of revision for patients 65 years or older (Tables HT63 and HT64 and Figure HT36).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-63.png"><img class="aligncenter size-full wp-image-4327" title="Table HT 63" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-63.png?w=529&#038;h=142" alt="" width="529" height="142" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-64.png"><img class="aligncenter size-full wp-image-4328" title="Table HT 64" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-64.png?w=529&#038;h=116" alt="" width="529" height="116" /></a></p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-36.png"><img class="aligncenter size-full wp-image-4329" title="Figure HT 36" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-36.png?w=529&#038;h=392" alt="" width="529" height="392" /></a></p>
<p>Females have twice the risk of revision compared to males (seven year cumulative percent revision of 9.3% and 4.5% respectively) (Tables HT65 and HT66 and Figure HT37).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-65.png"><img class="aligncenter size-full wp-image-4330" title="Table HT 65" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-65.png?w=529&#038;h=121" alt="" width="529" height="121" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-66.png"><img class="aligncenter size-full wp-image-4331" title="Table HT 66" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-66.png?w=529&#038;h=99" alt="" width="529" height="99" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-37.png"><img class="aligncenter size-full wp-image-4332" title="Figure HT 37" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-37.png?w=529&#038;h=379" alt="" width="529" height="379" /></a></p>
<p>There is no age related difference in the risk of revision for females. The age related revision risk is only associated with males (Tables HT67 and HT68 and Figures HT38 and HT39).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-67.png"><img class="aligncenter size-full wp-image-4333" title="Table HT 67" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-67.png?w=529&#038;h=176" alt="" width="529" height="176" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-68.png"><img class="aligncenter size-full wp-image-4334" title="Table HT 68" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-68.png?w=529&#038;h=156" alt="" width="529" height="156" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-38.png"><img class="aligncenter size-full wp-image-4335" title="Figure HT 38" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-38.png?w=529&#038;h=343" alt="" width="529" height="343" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-39.png"><img class="aligncenter size-full wp-image-4337" title="Figure HT 39" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-39.png?w=529&#038;h=371" alt="" width="529" height="371" /></a></p>
<h3>Head Size</h3>
<p>As previously reported, there is a relationship between femoral component head size and the risk of revision. Head sizes of 44mm or less have more than six times the risk of revision compared to head sizes 55mm or greater (Tables HT69 and HT70 and Figure HT40).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-69.png"><img class="aligncenter size-full wp-image-4338" title="Table HT 69" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-69.png?w=529&#038;h=141" alt="" width="529" height="141" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-70.png"><img class="aligncenter size-full wp-image-4339" title="Table HT 70" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-70.png?w=529&#038;h=125" alt="" width="529" height="125" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-40.png"><img class="aligncenter size-full wp-image-4340" title="Figure HT 40" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-40.png?w=529&#038;h=392" alt="" width="529" height="392" /></a></p>
<p>The effect of femoral component head size is evident in both males and females. Gender difference in outcome for total resurfacing hip replacement is largely due to differences in <a class="zem_slink" title="Femur head" href="http://en.wikipedia.org/wiki/Femur_head" rel="wikipedia">femoral head</a> size. There is no significant difference between gender in the risk of revision after adjusting for femoral component head size. Males and females with femoral component head size less than 50mm have a similar cumulative percent revision at seven years (10.2% and 10.3% respectively). Males and females with head sizes 50mm or greater also have a similar seven year cumulative percent revision (3.5% and 3.3% respectively) (Tables HT71 and HT72 and Figure HT41).</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-71.png"><img class="aligncenter size-full wp-image-4341" title="Table HT 71" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-71.png?w=529&#038;h=157" alt="" width="529" height="157" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-72.png"><img class="aligncenter size-full wp-image-4342" title="Table HT 72" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-72.png?w=529&#038;h=128" alt="" width="529" height="128" /></a>Revision diagnosis <a class="zem_slink" title="Cumulative incidence" href="http://en.wikipedia.org/wiki/Cumulative_incidence" rel="wikipedia">cumulative incidence</a> varies with head size. Head sizes less then 50mm have a higher incidence of the five most common reasons for revision (Figure HT42).</p>
<p><strong> <a href="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-42.png"><img class="aligncenter size-full wp-image-4343" title="Figure HT 42" src="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-42.png?w=529&#038;h=242" alt="" width="529" height="242" /></a></strong></p>
<p>&nbsp;</p>
<h3>Prosthesis Types</h3>
<p>The revision rates and yearly cumulative percent revision of total resurfacing hip <a class="zem_slink" title="Prosthesis" href="http://en.wikipedia.org/wiki/Prosthesis" rel="wikipedia">prostheses</a> are listed in Tables HT73 and HT74.</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-73.png"><img class="aligncenter size-full wp-image-4344" title="Table HT 73" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-73.png?w=529&#038;h=233" alt="" width="529" height="233" /></a><a href="http://earlstevens58.files.wordpress.com/2011/08/table-ht-74.png"><img class="aligncenter size-full wp-image-4345" title="Table HT 74" src="http://earlstevens58.files.wordpress.com/2011/08/table-ht-74.png?w=529&#038;h=241" alt="" width="529" height="241" /></a></p>
<p>There are five prostheses with over 1,000 observed component years, the BHR, ASR, Durom, Cormet and Mitch TRH. At five years, the BHR has the lowest cumulative percent revision (3.5%)compared to Cormet (6.0%), Durom (7.6%) and ASR (10.9%).</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2011/08/06/australian-orthopaedic-association-national-joint-replacement-registry-annual-report-2010/">Australian Orthopaedic Association National Joint Replacement Registry &#8211; Annual Report 2010</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/24/mr-michael-solomon-sydney-australia-surgeon-gives-advice-on-hip-replacement/">Mr. Michael Solomon, Sydney Australia Surgeon Gives Advice on Hip Replacement</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/26/mcminn-centre-data-suggests-how-bad-depuy-asr-was-v-others-on-the-market/">McMinn Centre Data Suggests How Bad DePuy ASR was v. Others on the Market</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/06/hip-resurfacing-dancer-back-at-rehersals-after-7-months/">Hip Resurfacing &#8211; Dancer Back at Rehersals after 7 Months</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/23/associate-professor-michael-j-neil-doesnt-recommend-resurfacing/">Associate Professor Michael J. Neil &#8211; Doesn&#8217;t Recommend Resurfacing</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/06/extracts-from-australian-orthopaedic-association-national-joint-replacement-registry-annual-report-2010/">Extracts from Australian Orthopaedic Association National Joint Replacement Registry &#8211; Annual Report 2010</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/26/mr-mcminn-inventor-of-the-bhr-gives-a-balanced-response-to-abc-4corners-program/">Mr McMinn, Inventor of the BHR Gives A Balanced Response to ABC 4Corners Program</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/04/revision-hip-replacement-rhr/">Revision Hip Replacement (RHR)</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/26/mhra-advice-for-patients/">MHRA Advice for Patients</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.everydayhealth.com/hip-pain/hip-resurfacing.aspx">Hip Resurfacing vs. Hip Replacement</a> (everydayhealth.com)</li>
</ul><br />Filed under: <a href='/category/australian-joint-registry/'>Australian Joint Registry</a>, <a href='/category/birmingham-hip-replacement-video/'>Birmingham Hip Replacement video</a>, <a href='/category/birmingham-hip-resurfacing/'>Birmingham Hip Resurfacing</a>, <a href='/category/depuy-asr-hip/'>DePuy ASR Hip</a>, <a href='/category/depuy-hip-litigation/'>DePuy Hip Litigation</a>, <a href='/category/depuy-hip-recall-3/'>DePuy Hip Recall</a>, <a href='/category/depuy-hip-replacement/'>DePuy Hip Replacement</a>, <a href='/category/depuy-hip-replacement-2/'>DePuy Hip Replacement</a>, <a href='/category/depuy-lawsuit/'>DePuy Lawsuit</a>, <a href='/category/elderly-patients-2/'>Elderly Patients</a>, <a href='/category/hip-implants/'>hip implants</a>, <a href='/category/hip-pain/'>Hip Pain</a>, <a href='/category/hip-replacement/'>Hip Replacement</a>, <a href='/category/hip-resurfacing-2/'>Hip Resurfacing</a>, <a href='/category/hip-revisions/'>Hip Revisions</a>, <a href='/category/johnson-johnson/'>Johnson &amp; Johnson</a>, <a href='/category/johnson-johnson-lawsuit/'>Johnson &amp; Johnson lawsuit</a>, <a href='/category/joint-replacement-2/'>Joint replacement</a>, <a href='/category/metal-on-metal-hip/'>Metal on metal hip</a>, <a href='/category/total-hip-replacement/'>Total Hip Replacement</a> Tagged: <a href='/tag/australia/'>Australia</a>, <a href='/tag/avascular-necrosis/'>Avascular necrosis</a>, <a href='/tag/bearing-surface/'>bearing surface</a>, <a href='/tag/femur-head/'>Femur head</a>, <a href='/tag/hip-replacement/'>Hip Replacement</a>, <a href='/tag/hip-resurfacing/'>hip resurfacing</a>, <a href='/tag/osteoarthritis/'>osteoarthritis</a>, <a href='/tag/patient/'>Patient</a>, <a href='/tag/prosthesis/'>Prosthesis</a>, <a href='/tag/rheumatoid-arthritis/'>Rheumatoid Arthritis</a>, <a href='/tag/surgery/'>surgery</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/4314/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/4314/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4314&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2011/08/06/primary-total-resurfacing-hip-replacement-%e2%80%93-extracts-from-australian-orthopaedic-association-national-joint-replacement-registry-%e2%80%93-annual-report-2010/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-31.png" medium="image">
			<media:title type="html">Figure HT 31</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-32.png" medium="image">
			<media:title type="html">Figure HT 32</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-57.png" medium="image">
			<media:title type="html">Table HT 57</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-58.png" medium="image">
			<media:title type="html">Table HT 58</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-33.png" medium="image">
			<media:title type="html">Figure HT 33</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-59.png" medium="image">
			<media:title type="html">Table HT 59</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-34.png" medium="image">
			<media:title type="html">Figure HT 34</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-60.png" medium="image">
			<media:title type="html">Table HT 60</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-61.png" medium="image">
			<media:title type="html">Table HT 61</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-62.png" medium="image">
			<media:title type="html">Table HT 62</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-35.png" medium="image">
			<media:title type="html">Figure HT 35</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-63.png" medium="image">
			<media:title type="html">Table HT 63</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-64.png" medium="image">
			<media:title type="html">Table HT 64</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-36.png" medium="image">
			<media:title type="html">Figure HT 36</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-65.png" medium="image">
			<media:title type="html">Table HT 65</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-66.png" medium="image">
			<media:title type="html">Table HT 66</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-37.png" medium="image">
			<media:title type="html">Figure HT 37</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-67.png" medium="image">
			<media:title type="html">Table HT 67</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-68.png" medium="image">
			<media:title type="html">Table HT 68</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-38.png" medium="image">
			<media:title type="html">Figure HT 38</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-39.png" medium="image">
			<media:title type="html">Figure HT 39</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-69.png" medium="image">
			<media:title type="html">Table HT 69</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-70.png" medium="image">
			<media:title type="html">Table HT 70</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-40.png" medium="image">
			<media:title type="html">Figure HT 40</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-71.png" medium="image">
			<media:title type="html">Table HT 71</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-72.png" medium="image">
			<media:title type="html">Table HT 72</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-ht-42.png" medium="image">
			<media:title type="html">Figure HT 42</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-73.png" medium="image">
			<media:title type="html">Table HT 73</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/table-ht-74.png" medium="image">
			<media:title type="html">Table HT 74</media:title>
		</media:content>
	</item>
		<item>
		<title>New Anti-Coagulants are Good BUT Caution Needed With Dabigatran in the Elderly</title>
		<link>https://earlsview.com/2011/08/05/new-anti-coagulants-are-good-but-caution-needed-with-dabigatran-in-the-elderly/</link>
		<comments>https://earlsview.com/2011/08/05/new-anti-coagulants-are-good-but-caution-needed-with-dabigatran-in-the-elderly/#comments</comments>
		<pubDate>Thu, 04 Aug 2011 20:57:13 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[Anticoagulant Drugs]]></category>
		<category><![CDATA[Dabigatran]]></category>
		<category><![CDATA[Elderly Patients]]></category>
		<category><![CDATA[Impaired Renal Function]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[Anticoagulant]]></category>
		<category><![CDATA[Atrial fibrillation]]></category>
		<category><![CDATA[Hadassah Medical Center]]></category>
		<category><![CDATA[iPhone]]></category>
		<category><![CDATA[Old age]]></category>
		<category><![CDATA[Pradaxa]]></category>
		<category><![CDATA[Rivaroxaban]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=4092</guid>
		<description><![CDATA[From Heartwire Caution Needed With Dabigatran in the Elderly Lisa Nainggolan August 4, 2011 (Paris, France) — New reports of &#8230;<p><a href="/2011/08/05/new-anti-coagulants-are-good-but-caution-needed-with-dabigatran-in-the-elderly/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4092&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<div id="titleblock">
<h2>From <a href="http://theheart.org/">Heartwire</a></h2>
<h3>Caution Needed With Dabigatran in <a class="zem_slink" title="Old age" href="http://en.wikipedia.org/wiki/Old_age" rel="wikipedia">the Elderly</a></h3>
<p id="authors">Lisa Nainggolan</p>
</div>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/call-for-caution-on-dabigatran.jpeg"><img class="alignleft size-full wp-image-4093" title="Call for caution on dabigatran" src="http://earlstevens58.files.wordpress.com/2011/08/call-for-caution-on-dabigatran.jpeg?w=529" alt=""   /></a>August 4, 2011 (<a class="zem_slink" title="Paris" href="http://www.paris.fr" rel="homepage">Paris, France</a>)<strong> </strong>— New reports of two elderly women faring badly when taking the novel anticoagulant dabigatran (<a class="zem_slink" title="Dabigatran" href="http://www.pradaxa.com" rel="homepage">Pradaxa</a>, Boehringer Ingelheim) for stroke prevention in atrial fibrillation (<a class="zem_slink" title="Atrial fibrillation" href="http://en.wikipedia.org/wiki/Atrial_fibrillation" rel="wikipedia">AF</a>) have prompted more discussion about the caution needed with this drug when treating the very old or those with renal impairment [<a href="http://theheart.org/article/1260157.do#bib_1">1</a>].</p>
<p>In an accompanying commentary [<a href="http://theheart.org/article/1260157.do#bib_2">2</a>], <strong>Dr Jeremy M Jacobs</strong> (<a class="zem_slink" title="Hadassah Medical Center" href="http://maps.google.com/maps?ll=31.7972222222,35.2419444444&amp;spn=1.0,1.0&amp;q=31.7972222222,35.2419444444%20%28Hadassah%20Medical%20Center%29&amp;t=h" rel="geolocation">Hadassah Medical Center</a>, <a class="zem_slink" title="Jerusalem" href="http://maps.google.com/maps?ll=31.7833333333,35.2166666667&amp;spn=0.1,0.1&amp;q=31.7833333333,35.2166666667%20%28Jerusalem%29&amp;t=h" rel="geolocation">Jerusalem, Israel</a>) and <strong>Dr Jochanan Stessman</strong> (Hebrew University-Hadassah Medical School, Jerusalem, Israel) say: &#8220;These cases require careful attention and serve to highlight a unique problem associated with oldest-old patients and novel drug therapy.<a href="http://earlstevens58.files.wordpress.com/2011/08/boehringer-ingelheim.jpeg"><img class="alignleft size-medium wp-image-4096" title="Boehringer Ingelheim" src="http://earlstevens58.files.wordpress.com/2011/08/boehringer-ingelheim.jpeg?w=300&#038;h=130" alt="" width="300" height="130" /></a></p>
<p>&#8220;It is of concern that those most likely to need anticoagulation are potentially those most at risk of its adverse effects—ie, frail, oldest-old patients among whom poorly diagnosed renal impairment, sarcopenia, and altered body composition are common. The lack of a specific antidote for dabigatran further renders this vulnerable group at risk,&#8221; they state.</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_f2.jpg"><img class="alignright size-full wp-image-4094" title="dabigatran_f2" src="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_f2.jpg?w=529" alt=""   /></a>One of the investigators of the RE-LY study— the pivotal trial on which approval of dabigatran for the prevention of stroke in AF was based—<strong>Dr Lars Wallentin</strong> (Uppsala Clinical Research Centre, Sweden), told heartwire that while it could not be proven that individuals who have fared badly on dabigatran would not also have done poorly on the alternative, traditional treatment of <strong>warfarin</strong>, he agrees that caution should be exercised with the new drug in the very elderly and frail. &#8220;Both the case reports and the commentary are relevant and appropriate,&#8221; he observes.</p>
<h3>Two Very Elderly, <a class="zem_slink" title="Frail Women" href="http://en.wikipedia.org/wiki/Frail_Women" rel="wikipedia">Frail Women</a> Fare Badly on Dabigatran</h3>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_approved.jpeg"><img class="alignleft size-full wp-image-4095" title="dabigatran_approved" src="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_approved.jpeg?w=529" alt=""   /></a>In most countries in which dabigatran is approved, the choices of dose are 150 mg twice daily, which was shown to be more effective than warfarin in RE-LY but carries a higher risk of bleeding, or 110 mg twice daily, which was shown to be equivalent to warfarin. In Canada, the EU, and other countries, dabigatran was approved for the stroke/AF indication in both the 110-mg and 150-mg doses, but the US made the controversial decision to approve only the 150-mg dose and an untested 75-mg dose for patients with severe renal impairment, stating that the data in favor of a 110-mg dose &#8220;were suggestive but not entirely convincing.&#8221;</p>
<p><strong>Dabigatran is primarily eliminated via the kidneys, so the patient prescribing information advises &#8220;dose adjustment&#8221; for renal impairment and notes an increased bleeding risk among those older than 75.</strong></p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/figure-1.png"><img class="alignleft size-medium wp-image-4097" title="Figure 1" src="http://earlstevens58.files.wordpress.com/2011/08/figure-1.png?w=300&#038;h=223" alt="" width="300" height="223" /></a>In one of the case reports just published, an 84-year-old woman taking 75 mg of dabigatran twice daily for AF, who weighed just 40 kg, developed massive rectal bleeding, had a cardiac arrest, and died, <strong>Dr Matthieu Legrand</strong> (Lariboisière Hospital, Paris, France) and colleagues report in the July 25, 2011 issue of the <em>Archives of Internal Medicine</em>. In the other case, an 89-year-old woman weighing 45 kg who had been taking 110-mg twice-daily dabigatran for AF for five months was found to have increased bleeding times and an elevated plasma level of dabigatran when tested prior to cochlear implant surgery. She had suffered recurrent nosebleeds for a week prior to this. Treatment with dabigatran was stopped, and the outcome was favorable.</p>
<h3>110 Mg Twice Daily a &#8220;Good Choice&#8221; for the Over-75s</h3>
<p>Jacobs and Stessman state in their editorial that they would like to see a subanalysis of the RE-LY data by age group. Another RE-LY investigator, <strong>Dr Salim Yusuf</strong> (McMaster University, Hamilton, ON), told <strong>heart<em>wire</em> </strong> that a &#8220;detailed analysis of RE-LY by age&#8221; is at an advanced stage.</p>
<blockquote><p>&#8220;In the meantime, increased vigilance is warranted for bleeding events among elderly patients, particularly those with renal impairment, as dabigatran enters the market and gains popularity and we accumulate more data via clinical trials, registries, and case reports [such as these],&#8221; the editorialists conclude.</p></blockquote>
<p><strong>Many of us in the RE-LY group believe that for those aged &gt;75 years, 110 </strong><strong>mg twice daily seems to be a good choice.</strong> </p>
<p>Wallentin says: &#8220;Based on RE-LY, we have evidence that 110 mg twice daily is as effective as warfarin with a lower risk of bleeding, and some doctors might prefer that dose because usually physicians like to stay on a safety course, especially for elderly patients with many other medications. Many of us in the RE-LY group believe that for those aged &gt;75 years, 110 mg twice daily seems to be a good choice.&#8221;</p>
<p>He and his coinvestigators believe the decision not to approve the 110-mg twice-daily dose of dabigatran in the US is thus leading to a reluctance to use the drug among doctors there, and they have repeatedly called for the FDA to reconsider its decision.</p>
<h3>Monitoring With Dabigatran May Even Be Required in High-Risk Groups</h3>
<p>Wallentin also told heart<em>wire</em> that a pharmacokinetic analysis, which is in press, shows that the 75-mg dose &#8220;might be recommended for those with a creatinine clearance at or below 30 mL/min,&#8221; as per the recommendation made by the FDA for <a href="http://earlstevens58.files.wordpress.com/2011/08/renal-function.jpeg"><img class="alignright size-full wp-image-4098" title="Renal Function" src="http://earlstevens58.files.wordpress.com/2011/08/renal-function.jpeg?w=529" alt=""   /></a>those with impaired renal function.</p>
<p>And he says that, in the future, &#8220;there might even be a reason to tailor the dabigatran dose based on measurements of dabigatran plasma concentrations or eventually thrombin time in patients at high risk of bleeding or risk of exposure to too-high dabigatran plasma concentrations.&#8221;</p>
<p>Asked by <strong>heart<em>wire</em> </strong>whether this would not negate one of the big advantages of dabigatran over warfarin—no monitoring required—he stressed that, if agreed—&#8221;and it still needs further discussion&#8221;—this would be necessary only in certain select groups, rather than in everyone, as is the case with warfarin.</p>
<p><em>Case report authors and editorialists report no conflicts of interest. Wallentin and Yusuf are investigators for RE-LY, a collaboration between Boehringer</em> <em>Ingelheim; McMaster University and Hamilton Health Sciences; the Uppsala Clinical Research Centre, Sweden; and Lankenau Institute for Medical Research</em></p>
<div>
<div>
<h4>References</h4>
<ol>
<li>Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. <em>Arch Intern Med</em> 2011; 171:1285-1288</li>
<li>Jacobs JM and Stessman J. New anticoagulant drugs among elderly patients. Is caution necessary?  <em>Arch Intern Med</em> 2011; 171:1287-1288</li>
</ol>
</div>
</div>
<div>
<div>
<h2>Authors and Disclosures</h2>
<h3>Journalist</h3>
<h4>Lisa Nainggolan</h4>
<p>Lisa Nainggolan is a journalist for theheart.org, part of the WebMD Professional Network. She has been with theheart.org since 2000. Previously, she was science editor of Scrip World Pharmaceutical News, covering news about research and development in the pharmaceutical industry, and a consultant editor of Scrip Magazine. Graduating in physiology from Sheffield University, UK, she began her career as a poisons information specialist at Guy&#8217;s Hospital before becoming a medical journalist in 1995. She can be reached at LNainggolan@webmd.net.</p>
</div>
</div>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2011/07/24/new-oral-anticoagulant-drugs-mechanisms-of-action/">New oral anticoagulant drugs &#8211; mechanisms of action</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.kevinmd.com/blog/2011/07/dabigatran-atrial-fibrillation-paradigm-shift.html">How dabigatran is an atrial fibrillation paradigm shift</a> (kevinmd.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/24/anti-coagulant-blockbuster-drugs-are-here-july-24-2011/">Anti-coagulant Blockbuster Drugs Are Here&#8230;</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://cardiophile.org/2011/08/bleeding-risk-of-oral-anticoagulants-in-the-very-elderly.html">Bleeding risk of oral anticoagulants in the very elderly</a> (cardiophile.org)</li>
<li class="zemanta-article-ul-li"><a href="http://www.kevinmd.com/blog/2011/07/top-stories-health-medicine-morning-july-26-2011.html">Top stories in health and medicine this morning, July 26, 2011</a> (kevinmd.com)</li>
<li class="zemanta-article-ul-li"><a href="http://clotconnect.wordpress.com/2011/07/20/lixiana-edoxaban-new-oral-blood-thinner/">Lixiana (Edoxaban): New Oral Blood Thinner</a> (clotconnect.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://clotconnectmd.wordpress.com/2011/07/20/lixiana-edoxaban-new-oral-anticoagulant/">Lixiana (Edoxaban): New Oral Anticoagulant</a> (clotconnectmd.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://clotconnectmd.wordpress.com/2011/06/23/eliquis-apixaban-good-news/">Eliquis (Apixaban) &#8211; Good News</a> (clotconnectmd.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://maturinuk.wordpress.com/2011/08/03/stroke-risk-stratification-scores-have-limited-prognostic-value-in-elders-with-af-general-medicine/">Stroke Risk-Stratification Scores Have Limited Prognostic Value in Elders with AF &#8211; General Medicine</a> (maturinuk.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.everydayhealth.com/dvt/dvt-treatment-side-effects.aspx">Managing the Side Effects of DVT Treatment</a> (everydayhealth.com)</li>
</ul><br />Filed under: <a href='/category/anticoagulant-drugs/'>Anticoagulant Drugs</a>, <a href='/category/dabigatran/'>Dabigatran</a>, <a href='/category/elderly-patients-2/'>Elderly Patients</a>, <a href='/category/impaired-renal-function/'>Impaired Renal Function</a>, <a href='/category/rivaroxaban-2/'>rivaroxaban</a> Tagged: <a href='/tag/anticoagulant/'>Anticoagulant</a>, <a href='/tag/atrial-fibrillation/'>Atrial fibrillation</a>, <a href='/tag/dabigatran/'>Dabigatran</a>, <a href='/tag/hadassah-medical-center/'>Hadassah Medical Center</a>, <a href='/tag/iphone/'>iPhone</a>, <a href='/tag/old-age/'>Old age</a>, <a href='/tag/pradaxa/'>Pradaxa</a>, <a href='/tag/rivaroxaban/'>Rivaroxaban</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/4092/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/4092/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4092&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2011/08/05/new-anti-coagulants-are-good-but-caution-needed-with-dabigatran-in-the-elderly/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/call-for-caution-on-dabigatran.jpeg" medium="image">
			<media:title type="html">Call for caution on dabigatran</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/boehringer-ingelheim.jpeg?w=300" medium="image">
			<media:title type="html">Boehringer Ingelheim</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_f2.jpg" medium="image">
			<media:title type="html">dabigatran_f2</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/dabigatran_approved.jpeg" medium="image">
			<media:title type="html">dabigatran_approved</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/figure-1.png?w=300" medium="image">
			<media:title type="html">Figure 1</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/renal-function.jpeg" medium="image">
			<media:title type="html">Renal Function</media:title>
		</media:content>
	</item>
	</channel>
</rss>
